Wiley BROS. Aintree Capital LLC Raises Stake in Pfizer Inc. (NYSE:PFE)

Wiley BROS. Aintree Capital LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 24,530 shares of the biopharmaceutical company’s stock after purchasing an additional 507 shares during the period. Wiley BROS. Aintree Capital LLC’s holdings in Pfizer were worth $900,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Worth Asset Management LLC bought a new position in shares of Pfizer in the first quarter worth $29,000. 25 LLC purchased a new position in Pfizer during the first quarter worth about $25,000. Freedom Wealth Alliance LLC bought a new position in Pfizer in the 4th quarter worth about $35,000. Macroview Investment Management LLC raised its holdings in shares of Pfizer by 70.0% in the 1st quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 396 shares in the last quarter. Finally, Sanctuary Wealth Management L.L.C. bought a new stake in shares of Pfizer during the 4th quarter valued at about $50,000. Institutional investors own 68.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PFE. StockNews.com initiated coverage on shares of Pfizer in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $47.00 to $40.00 in a research report on Thursday, June 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a research report on Tuesday, September 5th. Morgan Stanley lowered their price target on Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets cut their price objective on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a report on Wednesday, August 2nd. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $46.35.

Pfizer Stock Performance

Shares of PFE stock opened at $34.15 on Friday. The company has a market capitalization of $192.81 billion, a P/E ratio of 9.08, a PEG ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a fifty-two week low of $33.54 and a fifty-two week high of $54.93. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The stock has a 50 day moving average price of $35.86 and a two-hundred day moving average price of $38.06.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.10. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $13.36 billion. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The firm’s revenue for the quarter was down 54.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.04 EPS. Analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were paid a $0.41 dividend. The ex-dividend date of this dividend was Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.80%. Pfizer’s payout ratio is presently 43.62%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.